Interchange Capital Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Interchange Capital Partners’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$124K	Buy	23,464 +3,000	+15%	+$11.6K	0.04%	275
2025 Q4	$83.7K	Buy	20,464 +1,363	+7%	+$6.75K	0.02%	419
2025 Q3	$93.2K	Sell	19,101 -829	-4%	-$4.35K	0.02%	360
2025 Q2	$101K	Sell	19,930 -5,787	-23%	-$28.4K	0.02%	277
2025 Q1	$136K	Sell	25,717 -5,106	-17%	-$37.2K	0.04%	264
2024 Q4	$202K	Sell	30,823 -4,664	-13%	-$31.4K	0.07%	239
2024 Q3	$234K	Buy	35,487 +907	+3%	+$6.5K	0.08%	235
2024 Q2	$268K	Buy	34,580 +2,349	+7%	+$20.5K	0.1%	207
2024 Q1	$332K	Buy	32,231 +9,438	+41%	+$105K	0.22%	111
2023 Q4	$224K	Buy	+22,793	New	+$163K	0.17%	136

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Interchange Capital Partners's RXRX Position: Q1 2026 in Review

Interchange Capital Partners increased its Recursion Pharmaceuticals (RXRX) stake by 15% in Q1 2026, buying an estimated $11.6K and bringing the position to 23,464 shares worth $124K. The position accounts for 0.04% of the portfolio, ranked #275.

Interchange Capital Partners first reported a position in RXRX in Q4 2023 and has held it in 10 quarters since. The position peaked at $332K in Q1 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Interchange Capital Partners held 23,464 shares of Recursion Pharmaceuticals worth $124K as of Q1 2026.
Interchange Capital Partners bought 3,000 Recursion Pharmaceuticals shares in Q1 2026, an estimated $11.6K.
Recursion Pharmaceuticals made up 0.04% of Interchange Capital Partners's portfolio in Q1 2026, its #275 holding.
Interchange Capital Partners first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Interchange Capital Partners's Recursion Pharmaceuticals position peaked at $332K in Q1 2024.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Interchange Capital Partners's 13F filing for Q1 2026, filed 24 Apr 2026.